Antibodies and related molecules that bind to PSCA proteins

• US 7,595,379 B2
• Filed: 05/17/2005
• Issued: 09/29/2009
• Est. Priority Date: 05/30/2003
• Status: Expired due to Fees

• Current Assignee: Agensys, Inc. (Astellas Pharma Incorporated)
• Original Assignee: Agensys, Inc. (Astellas Pharma Incorporated)
• Inventors: Gudas, Jean, Raitano, Arthur B., Morrison, Karen Jane Meyrick, Morrison, Robert Kendall, Jia, Xiao-Chi, Challita-Eid, Pia M., Jakobovits, Aya, Shao, Hui
• Primary Examiner(s): Canella; Karen A
• Assistant Examiner(s): Reddig; Peter J
• Application Number:
  US11/131,648
• Publication Number:
  US 20050221400A1
• Time in Patent Office: 1,596 Days
• Field of Search: None
• US Class Current: 530/388.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/53 DNA (RNA) vaccination
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 39/0011 Cancer antigens
• CPC Class Codes: A61K 51/1051 the tumor cell being from breast, e.g. the antibody being herceptin
• CPC Class Codes: A61K 51/1054 the tumor cell being from lung
• CPC Class Codes: A61K 51/1057 the tumor cell being from liver or pancreas
• CPC Class Codes: A61K 51/106 the tumor cell being from kidney or bladder
• CPC Class Codes: A61K 51/1072 the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or prostate
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: C07K 14/4748 Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
• CPC Class Codes: C07K 14/705 Receptors; Cell surface antigens; Cell surface determinants tumour specific antigens C07K14/4748
• CPC Class Codes: C07K 16/30 from tumour cells
• CPC Class Codes: C07K 16/3069 Reproductive system, e.g. ovaria, uterus, testes, prostate
• CPC Class Codes: C07K 2317/34 Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/734 Complement-dependent cytotoxicity [CDC]
• CPC Class Codes: C07K 2317/77 Internalization into the cell
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
• CPC Class Codes: G01N 33/566 using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
• CPC Class Codes: G01N 33/57415 : of breast
• CPC Class Codes: G01N 33/57434 : of prostate
• CPC Class Codes: G01N 33/57492 : involving compounds localized on the membrane of tumor or cancer cells

Abstract

Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The PSCA gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with PSCA can be used in active or passive immunization.

Claims

1. A monoclonal antibody or fragment thereof comprising an antigen binding site that binds specifically to a PSCA protein comprising the amino acid sequence of SEQ ID NO:

2, and wherein the monoclonal antibody comprises the amino acid sequence of the V_H region and V_L region of the antibody secreted by the hybridoma assigned A.T.C.C. Accession No.;

PTA-6701.

2. The monoclonal antibody or fragment thereof of claim 1, wherein the antibody is coupled to a detectable marker, a toxin, a therapeutic agent, or a chemotherapeutic agent.

3. The monoclonal antibody or fragment thereof of claim 2, wherein the detectable marker is a radioisotope, a metal chelator, an enzyme, a fluorescent compound, a bioluminescent compound or a chemiluminescent compound.

4. The monoclonal antibody or fragment thereof of claim 3, wherein the radioisotope comprises ²¹²Bi, ¹³¹I, ¹³¹In, ⁹⁰Y, ¹⁸⁶Re, ²¹¹At, ¹²⁵I, ¹⁸⁸Re, ¹⁵³Sm, ²¹³Bi, ³²P, or Lu.

5. The monoclonal antibody or fragment thereof of claim 2, wherein the toxin comprises ricin, ricin A chain, doxorubicin, daunorubicin, a maytansinoid, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinbiastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin, Pseudomonas exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha sarcin, gelonin, mitogellin, restrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, glucocorticoid, auristatins, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolastatin, cc1065, or a cisplatin.

6. A hybridoma that produces the monoclonal antibody of claim 1.

7. A pharmaceutical composition that comprises the monoclonal antibody or fragment thereof of claim 1 in a unit dose form.